Skip to content
Decades of innovating medical aesthetics research Did you know?

Your conscientious biotech CRO

Access research excellence
The first CRO in the world to achieve HRPP accreditation Benefits to your clinical study
Pioneering ethical advancements in aesthetics across the globe Explore our medical aesthetics solutions
Research with a Conscience® Discover the ethica CRO difference

Driving Ethical Excellence in Biotech Clinical Research

Decades of experience in biotech make ethica a trusted partner for projects that are complex in nature. ethica CRO provides biopharmaceutical companies integrity of data through responsiveness, accuracy, and efficiency for the well-being of all research participants.

1st CRO in the world to have achieved HRPP accreditation

Only CRO in the world to have achieved accreditation from 3 different accrediting bodies

Played a pivotal role in shaping the neurotoxin application landscape

4 out of 5 studies are focused in medical aesthetics


Integrated research participants as partners in research since 2002

Our CRO Services

Medical Aesthetics

Our expertise spans the full spectrum of aesthetic medicine, ensuring that new treatments not only meet the highest standards of quality but also address the diverse needs of patients seeking aesthetic enhancements. Our Medical Aesthetics CRO services stand at the forefront of this journey, offering a comprehensive suite of services designed to bring groundbreaking treatments from concept to reality. With a focus on safety, efficacy, and regulatory compliance, we support the development and testing of innovative solutions in:

Our CRO Expertise

ethica CRO’s multidisciplinary team of industry leaders has extensive scientific expertise and a depth of clinical management experience to flawlessly manage your clinical development program. 

Gain efficiencies in your study without compromising quality or ethical standards. 

Our extensive experience designing and conducting studies using various designs in medical aesthetics, dermatology, neurology, respiratory disorders, medical devices, and Investigator Initiated Trials will save you time and effort, because we do it right, the first time. 

Meet your clinical objectives within budget and experience true ethical acceleration™. 

A CRO That Puts Quality First

Our Commitment to You

At ethica CRO, the research participant lies at the heart of what we do. ethica CRO is the 1st accredited Contract Research Organization in the world and an industry leader in research ethics. We take pride in delivering superior client outcomes while ensuring the welfare, safety and rights of research participants. We rely on our human research protection program, quality management system, and innovative data technology to deliver highly responsive clinical research services according to the highest standards of ethical and scientific practice.

Case Studies

Case Study: Innovative Advances in Scar Management Using an Injectable Peptide

Medical Aesthetics
This case study showcases a scar treatment project by a US-based biotechnology company, leveraging fibromodulin-based peptides. Facing the challenge of enhancing both cosmetic and functional wound outcomes, ethica CRO employed the Northwestern University Scar Model for a comprehensive assessment through a double-blind, multicenter study.

Investigator-Initiated Trials

Our team at ethica CRO managed a series of investigator-initiated trials (IITs) for aUS-based pharmaceuticals company. The main objective of these trials was to demonstrate the efficacy of botulinum toxin (BTX) for a number of off-label indications for aesthetic applications, as BTX was only approved for the treatment of glabellar lines at the time. Another purpose of these IITs was to enhance understanding of the effects and impacts of this drug, such as patient satisfaction, diffusion, duration of action, and social perception, among other factors.

Ensuring Data Consistency within a Diverse CF Population

Respiratory Disease
Hundreds of millions of people around the world suffer from respiratory diseases—asthma, cystic fibrosis (CF), and bronchiectasis being among the most prevalent conditions. CF affects 1 in every 3600 children born in Canada, making it the most common fatal genetic disease in our country. There is currently no cure for CF, but there exist treatment options that have been shown to improve the symptoms and quality of life of people living with this debilitating condition.

Meeting Unique Technical Challenges: The Case of FDA’s First Approval of a Dermal Filler for the Treatment of Acne Scars

Acne is the most common skin disorder in the U.S. affecting 40-50 million people. Up to 95% of people with acne may go on to suffer from scarring. Acne scarring can have significant impact on well-being and quality of life, particularly for people with moderate to severe acne scarring.